Biopharmaceutical company Rezolute has initiated a Phase II proof-of-concept study for RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of diabetic macular oedema (DMO). The current standard of care for DMO is anti-vascular growth factor (anti-VEGF) injections into the eye, requiring repeated administration over recurring periods of time […]
